Login / Signup

Prospective, controlled, blinded, randomized crossover trial evaluating the effect of maropitant versus ondansetron on inhibiting tranexamic acid-evoked emesis.

Marta E KantykaCarolina MeiraRegula Bettschart-WolfensbergerSonja HartnackAnnette P N Kutter
Published in: Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) (2020)
The neurokinin 1 receptor antagonist maropitant at the dose used, administered IV 10 minutes before 50 mg/kg TXA, was effective in preventing vomiting compared with ondansetron and placebo. Our results support the prophylactic IV administration of maropitant in dogs that are scheduled to receive TXA.
Keyphrases
  • placebo controlled
  • phase iii
  • double blind
  • chemotherapy induced
  • phase ii
  • open label
  • study protocol
  • clinical trial
  • signaling pathway
  • randomized controlled trial